Pascal Soriot’s been pushing for US-sized CEO pay for more than a decade. Now he’s finally getting it

Back in 2013, Pascal Soriot’s first full year at the helm of a tottering AstraZeneca, he landed a pay package worth about $5.5 million. By pharma CEO standards, it wasn’t much. And he likely wasn’t cheerful about the number.

Unlike just about every PR-conscious CEO in the industry, Soriot has from time to time voiced his displeasure about his pay, risking the inevitable grumbling that would come from everyone else in the company making far, far less.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Growing up in poverty may influence the wiring of a child’s brain, study suggests

A new study from Washington University School of Medicine in St. Louis suggests that growing up in poverty may influence the wiring of a child’s

June 27, 2023

What Cancer Did Jimmy Buffett Have?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

September 10, 2023

How Emergency Departments Can Drive Better Outpatient Care for Atrial Fibrillation and Stroke

JR Finkelmeier, Business Leader, ECG Solutions at Philips Today’s hospital emergency departments (EDs) face formidable challenges as they strive to deliver high-quality care to more

August 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.